Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il, 81442, Saudi Arabia.
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Cairo, 11651, Egypt.
Int J Nanomedicine. 2024 Nov 7;19:11415-11432. doi: 10.2147/IJN.S477001. eCollection 2024.
Atorvastatin (ATV), a medication used to reduce cholesterol levels, possesses properties that can counteract the damaging effects of free radicals and reduce inflammation. However, the administration of ATV orally is associated with low systemic bioavailability due to its limited capacity to dissolve in water and significant first-pass effect. This study aimed to assess the appropriateness of employing nano-vesicles for transdermal administration of ATV in order to enhance its anti-inflammatory effects.
ATV-loaded transethosomes (ATV-TEs) were optimized using the 3 Box-Behnken design. The ATV-TEs that were created were evaluated for their vesicle size, encapsulation efficiency (% EE), and percent release of drug. The optimum formulation was integrated into a hydroxypropyl methylcellulose (HPMC) emulsion-based gel (ATV-TEs emulgel) using jojoba oil. ATV-TEs emulgel was examined for its physical characteristics, ex vivo permeability, histological, and anti-inflammatory effect in a rat model of inflamed paw edema.
The optimized transethosomes exhibited a vesicle size of 158.00 nm and an encapsulation efficiency of 80.14 ± 1.42%. Furthermore, the use of transethosomal vesicles effectively prolonged the release of ATV for a duration of 24 hours, in contrast to the pure drug suspension. In addition, the transethosomal emulgel loaded with ATV exhibited a 3.8-fold increase in the transdermal flow of ATV, in comparison to the pure drug suspension. ATV-TEs emulgel demonstrated a strong anti-inflammatory impact in the carrageenan-induced paw edema model.
This was evident from the significant reduction in paw edema, which was equivalent to the effect of the standard anti-inflammatory medicine, Diclofenac sodium.
In summary, transethosomes, as a whole, might potentially serve as an effective method for delivering drugs via the skin. This could improve the ability of ATV to reduce inflammation by increasing its absorption through the skin.
阿托伐他汀(ATV)是一种用于降低胆固醇水平的药物,具有对抗自由基损伤和减轻炎症的特性。然而,由于其在水中的溶解度有限且具有显著的首过效应,口服给药的 ATV 全身生物利用度较低。本研究旨在评估采用纳米囊泡经皮给药 ATV 的适宜性,以增强其抗炎效果。
采用 3 因素 3 水平 Box-Behnken 设计优化 ATV 载纳米传递体(ATV-TEs)。考察所得 ATV-TEs 的囊泡粒径、包封率(% EE)和载药量累积释放度。将最佳处方制成以霍霍巴油为油相的羟丙甲纤维素(HPMC)乳剂凝胶(ATV-TEs 乳凝胶)。考察 ATV-TEs 乳凝胶的物理性质、体外透皮特性、组织学和大鼠炎症性足肿胀模型中的抗炎作用。
优化的纳米传递体粒径为 158.00nm,包封率为 80.14±1.42%。此外,与纯药物混悬剂相比,使用纳米传递体囊泡能有效延长 ATV 的释放时间,达 24 小时。而且,载 ATV 的纳米传递体乳凝胶使 ATV 的经皮渗透流量增加 3.8 倍,优于纯药物混悬剂。在角叉菜胶诱导的足肿胀模型中,ATV-TEs 乳凝胶表现出较强的抗炎作用。
这从足肿胀的显著减轻中得到证实,与标准抗炎药物双氯芬酸钠的效果相当。
总之,纳米传递体作为一种整体,可能成为一种有效的经皮给药方法。这可以通过增加皮肤吸收来提高 ATV 抗炎的能力。